Dalian Wonful Pharmaceutical Co., Ltd.

Dalian Wonful Pharmaceutical Co., Ltd was formerly known as Dalian Jinyi Pharmaceutical Factory, which was established in 1987 in Jinzhou District of Dalian city. It is a large-scale private enterprise engaged in the R&D, production and sales of high-end API and advanced intermediates. In 2010, it was moved to No. 50 Luanxiu Road, Changxing Island Economic Zone, Dalian. In 2014, it was officially renamed Dalian Wonful Pharmaceutical Co., Ltd (hereinafter referred to as "Wonful Pharmaceutical") . Registered capital 90 million RMB, covers an area of 20,000 square meters, building area 6000 square meters, including API workshop I, warehouse, office building, API workshop II and R&D center, there are 98 employees. The second phase of the project is currently under construction, covering an area of 70,000 square meters, with an estimated investment of 300 million RMB. Our company is located in Dalian Changxing Island National Park, one of the seven national petrochemical bases planned by the country, and it is positioned in the characteristic API and novel CDMO business. The company's market positioning is in the European and American regulated markets and large domestic pharmaceutical companies and It is a key supporting enterprise in Changxing Island Park.

Wonful Pharmaceutical has 5 APIs and 25 formulations. In 2015, the API passed the new national GMP certification and was officially put into production in December 2015. The company's main products are APIs and advanced intermediate products. Wonful Pharmaceutical passed the audits of many international well-known companies, including the pre-audit of the world's largest pharmaceutical company, Pfizer. Products are exported to Italy, Germany, France, South America, North America, India, and other countries in the world.

Wonful Pharmaceutical relies on the strong R&D and market development advantages of its parent company Beijing Mediking Biopharm Co., Ltd. Relying on the company's original full-process technical solution, established Chinese API Technology Union “CATU”. Through the novel CDMO business model, Our company is building the largest API and advanced pharmaceutical intermediate factory in the north. Undertake customized production projects of Chinese innovative drugs and generic drugs under the international regulated market and MAH dividend.

Since the establishment of the company, we insist on bottom-up management system，The management of the whole staff is based on the management purpose of employee satisfaction and customer satisfaction, adhering to continuous innovation, pursue excellent enterprise spirit, provide customers with a large number of high-quality raw materials and intermediates. Has been fully recognized and affirmed by our customers. On the premise of solving the environmental protection problem, it will occupy a certain position in the future pharmaceutical industry.

Our company is determined to work with partners to build a leading international and domestic pharmaceutical chemical company